Table 1.
Clinical characteristics and demographics of male and female lung cancer patients.
| male patients n = 152 |
female patients n = 134 |
p-value | |
|---|---|---|---|
| Age, mean ± SD | 67.01 ± 8.90 | 66.17 ± 10.92 | 0.477 |
| PY, mean ± SD | 44.74 ± 28.15 | 35.02 ± 28.1 | 0.005 |
| Ever-smoker, % | 92.1 | 86.3 | 0.180 |
| Body mass index, mean ± SD | 25.96 ± 5.11 | 25.19 ± 5.04 | 0.228 |
| Comorbities | |||
| COPD, % | 55.2 | 46.4 | 0.186 |
| Lung fibrosis, % | 1.4 | 2.4 | 0.886 |
| Lung function | |||
| FEV1 %, mean ± SD | 71.2 ± 24.41 | 70.23 ± 22.18 | 0.768 |
| TLCO SB %, mean ± SD | 58.8 ± 20.62 | 56.05 ± 17.88 | 0.373 |
| Histology | 0.190 | ||
| Squamous cell carcinoma, % | 21.1 | 20.9 | 1.000 |
| Adenocarcinoma, % | 50.0 | 58.2 | 0.204 |
| Adenosquamous carcinoma, % | 3.9 | 1.5 | 0.370 |
| Small-cell lung cancer, % | 16.4 | 15.7 | 0.987 |
| Large-cell cancer, % | 3.9 | 0 | 0.056 |
| Carcinoid, % | 2.6 | 3.0 | 1.000 |
| Immunohistochemistry and molecular pathology | |||
| PD-L1 status (%), median (IQR) | 4.0 (1.00, 40.00) | 5.00 (1.00; 51.5) | 0.535 |
| PD-L1≥50 %, % | 23.4 | 26.8 | 0.623 |
| Mutation, % | 71.8 | 73.6 | 0.907 |
| Treatable mutations, % (of all mutations) | 29.7 | 52.2 | 0.011 |
| Stage | 0.349 | ||
| IA1, % | 1.3 | 2.2 | |
| IA2, % | 4.6 | 9.0 | |
| IA3, % | 3.9 | 6.7 | |
| IB, % | 4.6 | 3.7 | |
| IIA, % | 0 | 2.2 | |
| IIB, % | 6.6 | 5.2 | |
| IIIA, % | 11.8 | 11.2 | |
| IIIB, % | 11.8 | 9.0 | |
| IIIC, % | 6.6 | 4.5 | |
| IVA, % | 14.5 | 18.7 | |
| IVB, % | 32.9 | 26.9 | |
| Treatment | |||
| Surgery | 23.8 | 24.6 | 0.991 |
| Radiotherapy | 43.8 | 42.3 | 0.893 |
| Chemotherapy | 51.7 | 44.4 | 0.279 |
| Immunotherapy | 33.6 | 35.2 | 0.879 |
| Targeted treatment | 4.9 | 9.0 | 0.278 |